Emergent BioSolutions

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Emergent BioSolutions addresses revenue challenges, eyes market expansion opportunities

Emergent BioSolutions navigated revenue challenges in Q4 2022, focusing on core businesses and strategic initiatives with a strong financial outlook for 2023.
The company faces competition and market positioning challenges in the OTC space for NARCAN, while opportunities exist in market expansion and government contracts.
Balancing pricing strategies, securing procurement decisions, and extending credit facility maturity are key focus areas for sustained growth and profitability.
Overall, Emergent BioSolutions demonstrates resilience and adaptability in addressing market challenges while capitalizing on opportunities for growth and market expansion.

Emergent BioSolutions (EBS) excels in Q1 with FDA approvals and strategic sales

Emergent BioSolutions (EBS) delivered a robust Q1 performance with notable achievements in FDA approvals and strategic business decisions. While facing challenges in gross margin changes and insurance coverage discussions, EBS remains focused on growth opportunities and product innovation.

Emergent BioSolutions reports Q2 growth, shifts focus to core products

Emergent BioSolutions' Q2 2023 earnings call highlighted positive financial results, strong NARCAN Nasal Spray sales, and strategic shifts towards core products. The company provided updated guidance for 2023, focusing on revenue expectations and cost-saving measures. Analyst questions centered on revenue breakdown, restructuring efforts, and future growth prospects.

Emergent BioSolutions (EBS) exceeds Q3 expectations, focuses on growth

Emergent BioSolutions (EBS) demonstrated strong financial performance in Q3 2023, exceeding revenue and EBITDA expectations. The company's focus on core products, compliance, and cost reduction initiatives positions it well for future growth. Challenges include a rescheduled earnings release and the need to meet growing demand for NARCAN Nasal Spray.

Emergent BioSolutions reports solid Q4 performance and outlines growth strategies

Emergent BioSolutions showcased strong financial performance and operational progress in Q4 2023, setting the stage for a promising 2024.
The company's strategic focus on debt reduction, quality enhancement, and core product strength bodes well for future growth.
While challenges persist in managing product sales variability and addressing stakeholder inquiries, opportunities for expansion and success are abundant.

Emergent BioSolutions excels in Q1, raises 2024 outlook amid growth prospects

Emergent BioSolutions reported strong Q1 performance, raised profit outlook for 2024, and highlighted growth drivers for key products. The company's strategic actions to reduce costs, improve profitability, and focus on core businesses demonstrate a proactive approach to driving long-term value. Despite challenges like potential generic competition, EBS remains well-positioned to leverage growth opportunities and sustain its positive momentum.

Emergent BioSolutions (EBS) exceeds Q2 guidance, poised for growth

Emergent BioSolutions (EBS) delivered strong Q2 results, exceeding revenue guidance and showcasing operational improvements.
The company's strategic actions, product highlights, and financial performance position it well for future growth and value creation.
Challenges in revenue sustainability and operational changes exist, but opportunities in international expansion, partnerships, and innovation are key drivers.
Overall, Emergent's focus on public health preparedness, opioid crisis solutions, and strategic growth initiatives bode well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Emergent BioSolutions has had a rough go over the past couple of months resulting from a cross-contamination mishap at their Baltimore facility. Due to the cross contamination, the company had to toss millions of Johnson & Johnson vaccines. Consequently, the FDA put a halt on vaccine production at that facility.

Emergent BioSolutions: Punished For Answering The Call To Immediate Action

Radnor, Pennsylvania--(Newsfile Corp. - May 3, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021, inclusive (the "Class Period").Lead Plaintiff Deadline: June 18, 2021Website: https://www.ktmc.com/new-cases/emergent-biosolutions-inc-ebs?utm_source=PR&utm_medium=Link&utm_campaign=emergentContact: James Maro, Esq. (484) 270-1453Adrienne Bell, Esq. (484)...

Shareholder Alert: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.

RADNOR, Pa., May 1, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Emergent BioSolutions Inc. (NYSE:  EBS) ("Emergent") on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021 , inclusive (the "Class Period").

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.

New York, New York--(Newsfile Corp. - May 1, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through March 31, 2021, inclusive (the "Class Period") of the important June 18, 2021 lead plaintiff deadline.SO WHAT: If you purchased Emergent BioSolutions securities during the Class Period you may be entitled to compensation without payment of any out...

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline - EBS

Emergent BioSolutions Inc (NYSE: EBS) has manufactured over 115 million doses of drug substance used in the Johnson & Johnson (NYSE: JNJ) COVID-19 vaccine, 60 million doses of which are in vials and ready to deploy at U.S. regulators' discretion, reports Bloomberg. The contract manufacturer has been producing the J&J single-shot vaccine since late 2020, according to a source.

Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg

Radnor, Pennsylvania--(Newsfile Corp. - April 30, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") that a securities fraud class action lawsuit has been on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who purchased or acquired Emergent common stock during the Class Period may,...

Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. (EBS)

Emergent's (EBS) earnings in the first quarter of 2021 beat estimates while revenues miss the same. It lowers guidance for revenues from CDMO services.

Emergent (EBS) Beats on Q1 Earnings, Cuts Contract Revenue View

Emergent BioSolutions Inc (NYSE: EBS) said it hopes to respond to U.S. regulators within days on how to resolve the problems at its Baltimore plant, which have forced Johnson & Johnson (NYSE: JNJ) to halt U.S. manufacturing of their COVID-19 vaccine essentially. The FDA stopped J&J's vaccine production at the plant earlier this month while investigating an error that led to 15 million doses being ruined last month.

Emergent BioSolutions Hopeful To Restart Vaccine Production, Plans To Submit Response To FDA Within Days

SAN FRANCISCO--(BUSINESS WIRE)-- #Emergent--EMERGENT SHAREHOLDERS: June 18, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser

EMERGENT INVESTORS: June 18, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser

Emergent BioSolutions, Inc. (EBS) CEO Robert Kramer on Q1 2021 Results - Earnings Call Transcript

NEW YORK, April 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through March 31, 2021, inclusive (the "Class Period") of the important June 18, 2021 lead plaintiff deadline. SO WHAT: If you purchased Emergent BioSolutions securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - EBS

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 57.73% and -6.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Emergent Biosolutions (EBS) Q1 Earnings Top Estimates

Shares of Emergent BioSolutions (NYSE:EBS) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 15200.00% over the past year to $1.53, which beat the estimate of $1.12.

Emergent BioSolutions: Q1 Earnings Insights

San Francisco, California--(Newsfile Corp. - April 29, 2021) - Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now.Class Period: July 6, 2020 - Mar. 31, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/EBSContact an Attorney Now: EBS@hbsslaw.com844-916-0895Emergent BioSolutions (NYSE: EBS) Securities Fraud Class Action:Throughout the class period, Defendants touted Emergent's deals with J&J and AstraZeneca to produce their vaccine can

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact its Attorneys Now, Securities Fraud Class Action Filed, Application Deadline Established

GAITHERSBURG, Md., April 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter ended March 31, 2021.

Emergent BioSolutions Reports Financial Results for First Quarter 2021

SAN FRANCISCO--(BUSINESS WIRE)-- #EmergentClassAction--Investor alert: Lieff Cabraser announces class action securities litigation has been filed against Emergent BioSolutions Inc. (NYSE: EBS)

EMERGENT SHAREHOLDERS: June 18, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser

Philadelphia, Pennsylvania--(Newsfile Corp. - April 28, 2021) - Berger Montague is investigating potential securities fraud claims against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent" or the "Company") on behalf of investors who purchased Emergent securities between July 6, 2020 and March 31, 2021 (the "Class Period"). If you purchased Emergent securities during the Class Period, have questions concerning your rights or interests, or would like to discuss Berger Montague's investigation, please contact attorneys Andrew Abramowitz...

EBS Stock: Berger Montague Investigates Potential Securities Fraud Claims Against Emergent BioSolutions Inc. (EBS); Lead Plaintiff Deadline is June 18, 2021

Radnor, Pennsylvania--(Newsfile Corp. - April 27, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") investors that a securities fraud class action lawsuit has been filed in the United States District Court for the District of Maryland against Emergent on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021, inclusive (the "Class Period").Lead Plaintiff Deadline:...

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. - EBS

SAN FRANCISCO, April 27, 2021 /PRNewswire/ -- Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now.  Class Period: July 6, 2020 - Mar. 31, 2021 Lead Plaintiff Deadline: June 18, 2021 Visit: www.hbsslaw.com/investor-fraud/EBS Contact an Attorney Now: EBS@hbsslaw.com                                              844-916-0895 Emergent BioSolutions (NYSE: EBS) Securities Fraud Class Action: ­Throughout the class period, Defendants touted Emergent's deals with J&J and AstraZeneca to produce their vaccine candidates and separate production contract with the U.S. government.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact its Attorneys Now, Securities Fraud Case Pending, Firm Investigating CEO's Insider Sales

NEW YORK--(BUSINESS WIRE)-- #EBS--INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Emergent BioSolutions Inc.'s Directors and Officers for Breach of Fiduciary Duties – EBS

INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Emergent BioSolutions Inc.'s Directors and Officers for Breach of Fiduciary Duties – EBS

The go-to government contractor is in deep trouble. Should investors buy the dip?

Is There Any Hope Left for Emergent BioSolutions?

Boston, Massachusetts--(Newsfile Corp. - April 26, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Emergent BioSolutions Inc. (NYSE: EBS). The case is currently in the lead plaintiff stage. Investors who purchased EBS stock or other securities between July 6, 2020 and March 31, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Emergent to submit their information. Investors may...

EBS INVESTOR ALERT: Class Action Lawsuit Filed

The CEO of the Baltimore lab that botched 15 million doses of the Johnson & Johnson vaccine last month sold more than $10 million worth of shares in his company before it disclosed the disastrous mistake.

Lab CEO sold $10 million in stock before news of J&J vaccine mishap

The CEO of Emergent BioSolutions, the government contractor that destroyed 15 million doses of Johnson & Johnson's COVID-19 vaccine, sold more than $10 million worth of his stock in the company before its share prices plummeted.

CEO of COVID-19 vaccine maker sold $10M in stock before company destroyed Johnson & Johnson doses

Emergent BioSciences' stock lost more than half of its value since the disclosure that it ruined as many as 15 million doses of Johnson & Johnson's Covid-19 vaccine at its Baltimore plant. But the company's CEO dumped more than $11 million worth of stock ahead of the stock's massive decline.

News for Emergent BioSolutions Stock (EBS)